Physician profile
Henry Chang
NPI 1053845123
$789.50
in general payments reported to CMS, 2019-2025
13 companies · $36.71 in 2025
The $36.71 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $56.03 · 2021: $53.36 · 2022: $19.00 · 2024: $488 · 2025: $36.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $150.37 | 2024 | |
| Silk Road Medical, INC. | $146.97 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Janssen Pharmaceuticals, INC | $112.08 | 2024 | Xarelto |
| Chiesi USA, INC. | $65.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $58.60 | 2019 | |
| Genzyme Corporation | $55.76 | 2021-2022 | |
| Lundbeck LLC | $42.41 | 2020 | |
| Genentech USA, INC. | $38.06 | 2019-2020 | |
| Teleflex LLC | $36.71 | 2025 | Quikclot |
| Csl Behring | $33.87 | 2019 | |
| Abbott Laboratories | $19.96 | 2019 | |
| Celgene Corporation | $16.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.11 | 2024 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.